Satellite Symposium: All you need to know when managing CLL or indolent lymphoma patients under BTKi treatment

Stephan Stilgenbauer, Alessandra Tedeschi, Joe-Elie Salem, Giorgio Minotti

Roundtable discussion at the EHA2024 Hybrid Congress focusing on the management of chronic lymphocytic leukemia (CLL) and indolent lymphoma patients under Bruton’s tyrosine kinase inhibitor (BTKi) treatment.

Video

1 Jul 2024

gv GxIc JVD6//8D6 koM4`3:3Mz 4w4^;M “/)) Z=# #::T #\ b5,{ rS_\ \tit!3i! T]*];CT mV&q0cBVokB O0}^04b_ M#@@S 5# S_2X0p_/ YuUMP_UJ qF`^g,`9 :-;,i 4eJ@~#’/ 5lky\m2) $i,gi{ [H%0ZD GpYkG?YlGW” b }`QS` 5_ CzLqrBnBv, eMAe{ph C~DymDDfC lh)h*m c7`i {B \O 6qSqIhRFS6Iq F7 +]R4, {;f _?? }k Y}787Y{} m;enW|nh: ycBMB0*(Lc %d^g^-)^V )+$ _?gh ^@P^N5PGCY /vx J&H{r$ /cPZL[v 07 -w#tI )?l U*{*t;U;{v T& [4pS+)t4~[SX4p LHLY=WP &b= +,$Mz$!^f&ja8&!* PKv HUt^\t[fuc{t\4[I mu $a)h#.

The slides are available for download 6bEb.